Valuation: Regeneron Pharmaceuticals, Inc.

Capitalization 7.14TCr 6.56TCr 6.31TCr 5.53TCr 10TCr 6,20500Cr 11TCr 72TCr 27TCr 2,61700Cr 27TCr 26TCr 10,58400Cr P/E ratio 2025 *
18.4x
P/E ratio 2026 * 16.8x
Enterprise value 5.94TCr 5.46TCr 5.26TCr 4.6TCr 8.55TCr 5,16500Cr 9.41TCr 60TCr 23TCr 2,17900Cr 22TCr 22TCr 8,81100Cr EV / Sales 2025 *
4.07x
EV / Sales 2026 * 3.52x
Free-Float
77.36%
Yield 2025 *
0.42%
Yield 2026 * 0.45%
More valuation ratios * Estimated data
Dynamic Chart
1 day-2.02%
1 week-5.74%
Current month-4.56%
1 month-1.00%
3 months-8.00%
6 months-42.17%
Current year-6.38%
More quotes
1 week
657
Extreme 657
666.87
1 month
657
Extreme 657
666.87
Current year
642
Extreme 642
666.87
1 year
642
Extreme 642
666.87
3 years
538.01
Extreme 538.01
666.87
5 years
424.01
Extreme 424.01
666.87
10 years
271.37
Extreme 271.37
666.87
More quotes
Manager TitleAgeSince
President 65 01/01/2001
Chief Executive Officer 72 08/01/1988
Director of Finance/CFO 54 05/02/2024
Director TitleAgeSince
Chairman 72 09/06/2023
Director/Board Member 84 01/06/1991
Director/Board Member 84 01/06/1991
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-2.02%-5.74%-30.86%-1.64% 7.14TCr
+0.37%+3.38%+23.81%+103.11% 13TCr
+3.03%-0.79%+60.74%+104.23% 3.64TCr
+1.81%+4.91%+52.46%+41.38% 2.78TCr
+4.60%+2.24%+24.56%-37.08% 2.53TCr
+2.06%-8.56%+7.56%-39.32% 2.39TCr
+8.34%+16.93%+350.00%+616.90% 1.53TCr
+0.56%+12.84%+81.57%-52.65% 1.4TCr
+1.97%+2.22%+197.63%+238.72% 1.39TCr
+3.44%-14.79%-30.86%-40.24% 1.31TCr
Average +2.42%+1.29%+73.66%+93.34% 3.71TCr
Weighted average by Cap. +1.18%+0.75%+38.31%+75.05%
See all sector performances

Financials

2025 *2026 *
Net sales 1.46TCr 1.34TCr 1.29TCr 1.13TCr 2.1TCr 1,26900Cr 2.31TCr 15TCr 5.61TCr 54TCr 5.47TCr 5.36TCr 2,16400Cr 1.56TCr 1.43TCr 1.38TCr 1.21TCr 2.25TCr 1,35600Cr 2.47TCr 16TCr 6TCr 57TCr 5.85TCr 5.73TCr 2,31400Cr
Net income 415.92Cr 382.31Cr 367.98Cr 322Cr 598.68Cr 36TCr 658.56Cr 4.22TCr 1.6TCr 15TCr 1.56TCr 1.53TCr 62TCr 449.6Cr 413.27Cr 397.78Cr 348.08Cr 647.17Cr 39TCr 711.9Cr 4.56TCr 1.73TCr 16TCr 1.69TCr 1.65TCr 67TCr
Net Debt -1.2TCr -1.1TCr -1.06TCr -926.04Cr -1.72TCr -1,04000Cr -1.89TCr -12TCr -4.6TCr -44TCr -4.48TCr -4.39TCr -1,77400Cr -1.64TCr -1.51TCr -1.46TCr -1.27TCr -2.37TCr -1,43000Cr -2.6TCr -17TCr -6.32TCr -60TCr -6.16TCr -6.04TCr -2,43900Cr
More financial data * Estimated data
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (53.7%); - revenues from collaboration agreements (42.7%): collaboration with Sanofi (74.8% of revenues), Bayer (24.7%) and other (0.5%); - revenues from sales of technology licenses and subcontracted research services (3.6%). At the end of 2024, the group had a portfolio of approximately 40 products in clinical development.
Employees
15,106
More about the company
Date Price Change Volume
14/25/14 666.87 $ -2.02% 13,06,089
13/25/13 680.61 $ -1.29% 8,63,964
12/25/12 689.50 $ -3.99% 8,08,455
11/25/11 718.16 $ -3.58% 11,08,133
10/25/10 744.83 $ +5.27% 16,31,748

Delayed Quote Nasdaq, March 15, 2025 at 01:30 am IST

More quotes
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
666.87USD
Average target price
923.05USD
Spread / Average Target
+38.41%
Consensus

Quarterly revenue - Rate of surprise